Claims
- 1. A method of treating cancer comprising administering to a patient in need thereof a therapeutically effective amount of a composition comprising an aldehyde 5-oxo-1,2,4-triazine hydrazide compound selected from the group consisting of those with the formula:
- 2. A method according to claim 1 wherein said cancer is prostate cancer.
- 3. A method according to claim 1 wherein said cancer is breast cancer.
- 4. A method according to claim 1 wherein said cancer is leukemia.
- 5. A method according to claim 1 wherein said cancer is pancreatic cancer.
- 6. A method according to claim 1 wherein said cancer is lung cancer.
- 7. A method according to claim 1 wherein said cancer is colon cancer.
- 8. A method according to claim 1 wherein said cancer is a sarcoma.
- 9. A method according to claim 1 wherein said cancer is a lymphoma.
- 10. A method according to claim 1 wherein said aldehyde 5-oxo-1,2,4-triazine hydrazide compound is benzaldehyde, 2-hydroxy-, (4-hydro-5-oxo-1,2,4-triazin-3-yl)hydrazide or benzaldehyde, 2-hydroxy-, (4-hydro-5-oxo-6-methyl-1,2,4-triazin-3-yl)hydrazide, pharmaceutical salts and prodrug, metabolites thereof.
- 11. A method according to claim 1 wherein wherein R and R1 are independently selected from the group consisting of hydrogen, or alkyl wherein the alkyl group has up to 4 carbon atoms and wherein R3 is
- 12. A pharmaceutical composition comprising a therapeutically effective amount of a composition comprising an aldehyde 5-oxo-1,2,4-triazine hydrazide compound selected from the group consisting of those with the formula:
- 13. A pharmaceutical composition of claim 12 further comprising a pharmaceutical carrier.
- 14. A pharmaceutical composition according to claim 12 wherein R3 is
- 15. A liposome composition comprising an aldehyde 5-oxo-1,2,4-triazine hydrazide compound selected from the group consisting of those with the formula:
- 16. A liposome composition according to claim 15 selected from the group of consisting of unilamallar vesicle and multilamallar vesicles.
- 17. A liposome composition according to claim 16 formed from phospholipids cholesterol, stearylamine or phosphatidyl choline.
- 18. The pharmaceutical composition of claim 12 wherein the aldehyde 5-oxo-1,2,4-triazine hydrazide is a hydrochloride salt of benzaldehyde, 2-hydroxy-, (4-hydro-5-oxo-1,2,4-triazin-3-yl)hydrazide or benzaldehyde, 2-hydroxy-, (4-hydro-5-oxo-6-methyl-1,2,4-triazin-3-yl)hydrazide.
- 19. A pharmaceutical composition comprising a therapeutically effective amount of a composition comprising an 5-oxo-1,2,4-triazine hydrazine compound selected from the group consisting of those with the formula:
- 20. A pharmaceutical composition of claim 19 further comprising a pharmaceutical carrier.
Parent Case Info
[0001] The present application is a continuation application of U.S. Ser. No. 09/627,611 filed Jul. 28, 2000, incorporated by reference herein, and claims priority to said application under 35 U.S.C. 120.
Continuations (1)
|
Number |
Date |
Country |
Parent |
09627611 |
Jul 2000 |
US |
Child |
10364287 |
Feb 2003 |
US |